INT RODUCTI ON
Chronic Lymphocitic Leukemia (CLL) is one of the most frequent types of leukemia (22-30%), with an incidence rate ranging from 1 to 5,5 per 100,000 people 1 . Several therapeutic options are available for the treatment of the disease, including alkylating agents (chlorambucil, cyclophosphamide), purine analogues (fludarabine, cladribine) and monoclonal antibodies (rituximab) 2 . Although international guidelines are available, there is lack of information on current treatment choices in Brazil. The aim of the study was to identify treatment patterns or lines of chemotherapy treatments and the direct costs associated in patients with chronic lymphocytic leukemia (CLL) in the private healthcare system.
M ET HODS
Retrospective cohort analysis from the healthcare system database of Orizon company. Orizon has 102 health insurance companies and approximately 34% of patients in the private healthcare system in Brazil.
The period of analysis was January 2009 to December 2012. Eligibility criteria were patients with CLL (ICD-10 code C911) starting chemotherapy treatment from April 2009 to December 2012, followed until loss of followup. Chemotherapy regimens were identified based on concomitant drugs used in each patient. Treatment lines were defined based on significant interruption (>6 months) and/or change in chemotherapy regimen.
Descriptive statistics (mean, standard deviation and percentage of each treatment regimen) was conducted for two outcomes: chemotherapy costs and chemotherapy regimens.
R E S ULT S
163 patients met eligibility criteria, representing 859 cycles of chemotherapy. 41.7% of patients underwent more than one treatment regimen (Table 1) . Total chemotherapy direct costs were R$ 84,979.63 per patient. The three commonest treatment regimens were fludarabine, cyclophosphamide and rituximab (FCR), used by 81 patients (47.9%) with an average duration of 3.54 cycles and total costs of R$ 69,241.91 per patient; rituximab monotherapy, used by 44 patients or 27.0% of patients, with an average duration of 4.05 cycles and total costs R$ 59,543.12 per patient; and fludarabine and cyclophosphamide (FC), used in 19 patients (11.7%), with an average duration of 2.22 cycles and total cost of R$ 15,724.34 per patient (Table 2) . Table 2 . Average spent and cycles per user.
* Users may be counted in more than one cycle Chemotherapy drugs accounted for 72.8% of total costs, followed by other drugs (11%), other hospital costs (6.5%), hospital fees (5.0%) procedures (3.0%) and exams(1.7%). The commonest regimens were FCR (Fludarabine + Rituximab + Cyclophosphamide) with 32.9% of cycles in the period, Rituximab with 20.4%, R-CVP (rituximab + cyclophosphamide + vincristine + prednisone) with 7.7% and FR (Fludarabine + Rituximab) with 5.9% (Figure 2 ). The commonest drugs were: rituximab (78.6%), fludarabine (49.1%) and Cyclophosphamide (58.0%).
C ONCLU S ION L LI M ITATI ONS
• As with any retrospective database study, we are limited by the level of accuracy of the information recorded in the database.
• The rate of patients undergoing more than one line of therapy may be overestimated, since it was assumed that any interruption on the treatment meant switch to another line of therapy; • The abovementioned assumption would also lead to an underestimation of the average length of therapy and treatment-free interval.
C ONCLU S ION
FCR is the standard of care in CLL patients treated in the Brazilian Private Health System, and almost half of the patients undergo more than one treatment line, creating a significant financial burden to private payers (R$ 84,979.63 per patient). Approximately 41.7% of patients underwent more than one treatment regimen. Number of chemotherapy regimens (n = 163) 
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